BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Opinion

  AI Enables Companies to Break From the Herd in Drug Development

  Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI could change that.

  April 7, 2025

   · 

  6 min read

   · 

  Ruth Gross
• 

  IN PARTNERSHIP WITH DIA

  Beyond Neutrality: How Nonprofit Organizations Drive Healthcare Innovation and Collaboration

  Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ecosystem during a time of uncertainty.

  April 7, 2025

   · 

  7 min read

   · 

  BioSpace Insights
• 

  Legal

  Lilly’s Fight to Stop Zepbound Knockoffs Leads to Lawsuit Against Indianapolis Spa

  Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and repackaging them into separate doses.

  April 7, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Obesity

  Trump Scraps Biden’s Proposed Medicare Coverage for Obesity Drugs

  Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

  April 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Lyell Cuts 73 Employees as Part of LA Site Closure

  After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.

  April 7, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  MASH

  7 Late-Stage MASH Candidates That Could Reshape the Market

  Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by 2033.

  April 7, 2025

   · 

  6 min read

   · 

  Ben Hargreaves
• 

  Neuroscience

  Centessa’s Narcolepsy Drug Shows ‘Compelling’ Effect in Early Study

  Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting the company in a strong position in the $15 billion market.

  April 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Kennedy Changes Tune on MMR Vaccine as Second Child Dies of Measles

  Kennedy, a long-time opponent of vaccines, stated that the MMR vaccine is “the most effective way” to combat the measles outbreak, which has already claimed the lives of two children in the U.S.

  April 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication

  Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the hypothalamus taking Rhythm Pharmaceuticals’ Imcivree.

  April 7, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Neuroscience

  GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact

  GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

  April 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac